SGHT

+ Watchlist + Portfolio

Sight Sciences, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $8.47
52-Week Range: $3.19 – $9.24
Market Cap: $448.97M
P/E (TTM): —
EPS (TTM): -0.55
Dividend Yield: —

Advanced Metrics

Price/Book: 8.43
PEG Ratio: —
Return on Equity: -48.42%
Return on Assets: -10.84%
Gross Margin: 87.96%
Operating Margin: -16.62%
Profit Margin: -35.69%
Current Ratio: 4.95
Debt/Equity: 0.79
Total Debt: $41.97M
Free Cash Flow: $-8.61M
Revenue Growth: 19.50%
Earnings Growth: —
Enterprise Value: $411.19M

SGHT Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$71.33M	$81.06M	$79.87M	$77.36M
Cost of Revenue	$12.36M	$11.88M	$11.58M	$10.70M
Gross Profit	$58.97M	$69.17M	$68.28M	$66.67M
Research & Development	$22.86M	$17.56M	$17.99M	$14.61M
Selling, General & Admin	$120.06M	$108.89M	$100.83M	$89.16M
Operating Expenses	$142.92M	$126.45M	$118.82M	$103.77M
Operating Income	-$83.95M	-$57.27M	-$50.53M	-$37.10M
EBITDA	-$81.02M	-$49.41M	-$45.90M	-$32.79M
Pretax Income	-$86.19M	-$55.44M	-$51.27M	-$38.42M
Income Tax	$47.00K	$110.00K	$236.00K	$10.00K
Net Income	-$86.24M	-$55.55M	-$51.51M	-$38.43M
Diluted EPS	-1.80	-1.14	-1.03	-0.74
Diluted Shares	47.85M	48.63M	50.13M	52.15M

SGHT Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$185.00M	$138.13M	$120.36M	$91.97M
Receivables	$15.15M	$14.29M	$10.79M	$9.74M
Inventory	$6.11M	$7.85M	$6.33M	$7.77M
Current Assets	$209.68M	$162.87M	$139.77M	$112.73M
Total Assets	$213.07M	$166.65M	$142.84M	$115.30M
Current Liabilities	$17.82M	$12.25M	$15.47M	$11.03M
Long-Term Debt	$33.31M	$31.71M	$39.36M	$40.30M
Total Debt	$34.98M	$35.41M	$40.36M	$40.77M
Total Liabilities	$53.00M	$46.44M	$55.32M	$51.36M
Retained Earnings	-$239.24M	-$294.79M	-$346.30M	-$384.72M
Shareholders' Equity	$160.08M	$120.22M	$87.52M	$63.94M
Working Capital	$191.86M	$150.62M	$124.31M	$101.71M

SGHT Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$75.97M	-$47.18M	-$22.35M	-$29.69M
Capital Expenditure	-$970.00K	-$791.00K	-$385.00K	-$224.00K
Free Cash Flow	-$76.94M	-$47.98M	-$22.74M	-$29.92M
Depreciation & Amortisation	$710.00K	$614.00K	$712.00K	$487.00K
Stock-Based Compensation	$12.96M	$14.58M	$17.08M	$13.05M
Investing Cash Flow	-$970.00K	-$791.00K	-$385.00K	-$224.00K
Financing Cash Flow	$1.25M	$1.10M	$4.96M	$1.79M
Net Change in Cash	-$75.69M	-$46.87M	-$17.77M	-$28.13M

SGHT Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$17.51M	$19.56M	$19.91M	$20.39M	$19.70M
Cost of Revenue	$2.41M	$2.98M	$2.71M	$2.60M	$2.72M
Gross Profit	$15.09M	$16.59M	$17.20M	$17.79M	$16.98M
Research & Development	$4.43M	$4.39M	$3.35M	$2.44M	$2.55M
Selling, General & Admin	$24.52M	$23.87M	$21.75M	$19.02M	$26.84M
Operating Expenses	$28.95M	$28.25M	$25.10M	$21.46M	$29.39M
Operating Income	-$13.86M	-$11.67M	-$7.91M	-$3.67M	-$12.41M
EBITDA	-$12.70M	-$10.49M	-$6.84M	-$2.76M	-$11.60M
Pretax Income	-$14.11M	-$11.90M	-$8.25M	-$4.15M	-$12.97M
Income Tax	$41.00K	$40.00K	-$79.00K	$8.00K	$11.00K
Net Income	-$14.15M	-$11.94M	-$8.17M	-$4.16M	-$12.98M
Diluted EPS	-0.28	-0.23	-0.16	-0.08	-0.24
Diluted Shares	51.29M	51.82M	52.38M	53.08M	53.94M

SGHT Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$108.77M	$101.50M	$92.37M	$91.97M	$84.96M
Receivables	$9.42M	$9.61M	$9.74M	$9.74M	$10.60M
Inventory	$5.80M	$6.21M	$7.98M	$7.77M	$7.01M
Current Assets	$126.91M	$119.43M	$113.59M	$112.73M	$106.51M
Total Assets	$129.68M	$121.97M	$116.26M	$115.30M	$109.70M
Current Liabilities	$12.12M	$11.94M	$11.83M	$11.03M	$18.16M
Long-Term Debt	$39.58M	$39.82M	$40.07M	$40.30M	$36.74M
Total Debt	$40.46M	$40.57M	$40.69M	$40.77M	$41.76M
Total Liabilities	$52.05M	$51.96M	$51.97M	$51.36M	$55.80M
Retained Earnings	-$360.45M	-$372.39M	-$380.56M	-$384.72M	-$397.70M
Shareholders' Equity	$77.63M	$70.01M	$64.29M	$63.94M	$53.90M
Working Capital	$114.78M	$107.50M	$101.76M	$101.71M	$88.35M

SGHT Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$11.61M	-$7.54M	-$8.72M	-$1.83M	-$7.03M
Capital Expenditure	—	—	-$170.00K	—	-$60.00K
Free Cash Flow	-$11.61M	-$7.75M	-$8.89M	-$1.67M	-$7.09M
Depreciation & Amortisation	$149.00K	$125.00K	$105.00K	$108.00K	$103.00K
Stock-Based Compensation	$4.24M	$3.84M	$2.42M	$2.55M	$2.85M
Investing Cash Flow	$0.00	-$210.00K	-$170.00K	$156.00K	-$60.00K
Financing Cash Flow	$16.00K	$485.00K	$25.00K	$1.26M	$88.00K
Net Change in Cash	-$11.59M	-$7.27M	-$8.86M	-$406.00K	-$7.00M

Market Snapshot

About

Sight Sciences, Inc. is an ophthalmic medical device company focused on developing and commercializing innovative technologies for the treatment of prevalent eye diseases. The company specializes in surgical glaucoma products and dry eye disease treatments that aim to transform patient care through less invasive procedures. Sight Sciences markets its products to ophthalmologists and optometrists globally.